se 10 Search Results


dbco peg 4 nhs  (Chem Impex International)
95
Chem Impex International dbco peg 4 nhs
Dbco Peg 4 Nhs, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc12961533-135-6-12?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
dbco peg 4 nhs - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
ang ii  (Shanghai Korain Biotech Co Ltd)
93
Shanghai Korain Biotech Co Ltd ang ii
Ang Ii, supplied by Shanghai Korain Biotech Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc11464679-171-8-10?v=Shanghai+Korain+Biotech+Co+Ltd
Average 93 stars, based on 1 article reviews
ang ii - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
rat anti lcn2  (R&D Systems)
94
R&D Systems rat anti lcn2
Rat Anti Lcn2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc08153086-230-15-18?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
rat anti lcn2 - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier
fzd10  (Novus Biologicals)
90
Novus Biologicals fzd10
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
Fzd10, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pm25406648-350-31-34?v=Novus+Biologicals
Average 90 stars, based on 1 article reviews
fzd10 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
3 4 dihydroxy l phenylalanine  (Chem Impex International)
95
Chem Impex International 3 4 dihydroxy l phenylalanine
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
3 4 Dihydroxy L Phenylalanine, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pm35793554-233-23-41?v=Chem+Impex+International
Average 95 stars, based on 1 article reviews
3 4 dihydroxy l phenylalanine - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
contract exmar se539 10/17  (EXMAR GmbH)
90
EXMAR GmbH contract exmar se539 10/17
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
Contract Exmar Se539 10/17, supplied by EXMAR GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/10__1016_slash_j__jembe__2011__07__035-227-5-6?v=EXMAR+GmbH
Average 90 stars, based on 1 article reviews
contract exmar se539 10/17 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
force sensors optoforce omd-10-se-10n7  (OptoForce Ltd)
90
OptoForce Ltd force sensors optoforce omd-10-se-10n7
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
Force Sensors Optoforce Omd 10 Se 10n7, supplied by OptoForce Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc07297081-211-4-3?v=OptoForce+Ltd
Average 90 stars, based on 1 article reviews
force sensors optoforce omd-10-se-10n7 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
"vitr ic-10"—a qu ick- se t t ing , chemica l -hardening sodium silicate cement.  (US Stoneware)
90
US Stoneware "vitr ic-10"—a qu ick- se t t ing , chemica l -hardening sodium silicate cement.
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
"Vitr Ic 10"—A Qu Ick Se T T Ing , Chemica L Hardening Sodium Silicate Cement., supplied by US Stoneware, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/10__1021_slash_cen___v023n008__obc-21-16-1?v=US+Stoneware
Average 90 stars, based on 1 article reviews
"vitr ic-10"—a qu ick- se t t ing , chemica l -hardening sodium silicate cement. - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
tablets providing 0, 10, 20, 30 or se/d as l-selenomethionine  (Westar Nutrition Corp)
90
Westar Nutrition Corp tablets providing 0, 10, 20, 30 or se/d as l-selenomethionine
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
Tablets Providing 0, 10, 20, 30 Or Se/D As L Selenomethionine, supplied by Westar Nutrition Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pm10673907-24-24-25?v=Westar+Nutrition+Corp
Average 90 stars, based on 1 article reviews
tablets providing 0, 10, 20, 30 or se/d as l-selenomethionine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
transdutor linear de banda larga 5 — 10 mhz sonoace 8000 se  (Sonoace GmbH)
90
Sonoace GmbH transdutor linear de banda larga 5 — 10 mhz sonoace 8000 se
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
Transdutor Linear De Banda Larga 5 — 10 Mhz Sonoace 8000 Se, supplied by Sonoace GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pm19488530-68-0-12?v=Sonoace+GmbH
Average 90 stars, based on 1 article reviews
transdutor linear de banda larga 5 — 10 mhz sonoace 8000 se - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
5 – 10 mhz linear probe sonoace 8000 se  (Sonoace GmbH)
90
Sonoace GmbH 5 – 10 mhz linear probe sonoace 8000 se
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
5 – 10 Mhz Linear Probe Sonoace 8000 Se, supplied by Sonoace GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc06465072-2056-43-51?v=Sonoace+GmbH
Average 90 stars, based on 1 article reviews
5 – 10 mhz linear probe sonoace 8000 se - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
1.27- μ m thick chalcogenide film (ge 25 sb 10 se 65)  (SCHOTT)
90
SCHOTT 1.27- μ m thick chalcogenide film (ge 25 sb 10 se 65)
Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing <t>FZD10</t> expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.
1.27 μ M Thick Chalcogenide Film (Ge 25 Sb 10 Se 65), supplied by SCHOTT, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/se+10/pmc04354268-15-41-56?v=SCHOTT
Average 90 stars, based on 1 article reviews
1.27- μ m thick chalcogenide film (ge 25 sb 10 se 65) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing FZD10 expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.

Journal: Nature communications

Article Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.

doi: 10.1038/ncomms6406

Figure Lengend Snippet: Figure 3 | BRMS1L inhibits breast cancer cell invasion and EMT via suppressing FZD10 expression. (a) mRNA microarray (GSE61354) analysis reveals mRNA differentially expressed in MDA-MB-231 cells transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC) for 24 h. (b) qRT–PCR for the mRNA expression of WNT2B, WNT7A, WNT9B, WNT10B, FRAT1, FZD10, VANGL2, BMP8A, CAMK3B in mRNA microarray. ***Po0.001 as compared with NC. Bars correspond to mean±s.d. The data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups. (c) Western blotting for BRMS1L and FZD10 in T47D cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two BRMS1L-siRNAs. (d) Western blotting for BRMS1L and FZD10 in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). (e) E-cadherin and vimentin protein expression levels measured by western blotting in MCF-10A cells that were untreated (UT), mock transfected (mock) or transfected with GFP-siRNA or two FZD10-siRNAs. (f,g) Invasion of cancer cells measured by Boyden chamber assays for BT-474 (f) and MDA-MB-231 cells (g) treated as indicated. Bars correspond to mean±s.d. ***Po0.001 as compared with mock. Scale bars correspond to 50 mm. Student’s t-test was used for the comparison of two independent groups. (h) Immunohistochemical staining for FZD10 in primary breast cancer with or without regional lymph nodes (LN) metastasis and metastatic lymph nodes (LNMs). Scale bar corresponds to 50 mm. BRL, BRMS1L; E-cad, E-cadherin; Vim, Vimentin.

Article Snippet: Protein extracts were resolved in 8–15% SDS–polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes and probed with antibodies against E-cadherin (1:1,000, 3195S, CST), vimentin (1:1,000, AF2105, R&D), BRMS1L (1:1,000, NBP2-14362, Novus), FZD10 (1:500, NBP100826, Novus), JNK (1:1,000, 9258, CST), p-JNK (1:1,000, Thr183/Tyr185, 4668S, CST), b-catenin (1:4,000, ab16051, Abcam) and b-actin (1:25,000, A3854, Sigma).

Techniques: Expressing, Microarray, Transfection, Plasmid Preparation, Negative Control, Quantitative RT-PCR, Comparison, Western Blot, Immunohistochemical staining, Staining

Figure 5 | BRMS1L suppresses WNT3/FZD10/b-catenin pathway. (a) Wnt/b-catenin activity measured by TCF/LEF luciferase reporter assays in T47D cells that were mock transfected (mock), or transfected with GFP-siRNA or two BRMS1L-siRNAs and in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). Bars correspond to mean±s.d., ***Po0.001 as compared with GFP-siRNA, ###Po0.001 as compared with NC. (b,c) Wnt/b-catenin activities measured by TCF/LEF luciferase assays in MDA-MB-231 (b) and T47D cells (c) treated as indicated. Bars correspond to mean±s.d. **Po0.001 as compared with BRMS1L or BRMS1L-siRNA1. (d,e) Western blotting for nuclear (n) and cytoplasm (c) b-catenin in MDA-MB-231 (d) and T47D cells (e) treated as indicated. (f,g) Wnt/b-catenin activities measured by TCF/LEF luciferase assays (f) and b-catenin translocation (g) in MDA-MB-231cells treated as indicated. ***Po0.001 as compared with GFP-siRNA. (h,i) Wnt/b-catenin activities measured by TCF/LEF b-catenin translocation (h) and luciferase assays (i) in T47D cells treated as indicated. ***Po0.001 as compared with BRMS1L-siRNA1. b-cat, b-catenin; BRL, BRMS1L. Bars correspond to mean±s.d. These data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups in a,b,c,f,i.

Journal: Nature communications

Article Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.

doi: 10.1038/ncomms6406

Figure Lengend Snippet: Figure 5 | BRMS1L suppresses WNT3/FZD10/b-catenin pathway. (a) Wnt/b-catenin activity measured by TCF/LEF luciferase reporter assays in T47D cells that were mock transfected (mock), or transfected with GFP-siRNA or two BRMS1L-siRNAs and in MDA-MB-231 cells that were transfected with pcDNA3 vector carrying BRMS1L (BRMS1L) or negative control (NC). Bars correspond to mean±s.d., ***Po0.001 as compared with GFP-siRNA, ###Po0.001 as compared with NC. (b,c) Wnt/b-catenin activities measured by TCF/LEF luciferase assays in MDA-MB-231 (b) and T47D cells (c) treated as indicated. Bars correspond to mean±s.d. **Po0.001 as compared with BRMS1L or BRMS1L-siRNA1. (d,e) Western blotting for nuclear (n) and cytoplasm (c) b-catenin in MDA-MB-231 (d) and T47D cells (e) treated as indicated. (f,g) Wnt/b-catenin activities measured by TCF/LEF luciferase assays (f) and b-catenin translocation (g) in MDA-MB-231cells treated as indicated. ***Po0.001 as compared with GFP-siRNA. (h,i) Wnt/b-catenin activities measured by TCF/LEF b-catenin translocation (h) and luciferase assays (i) in T47D cells treated as indicated. ***Po0.001 as compared with BRMS1L-siRNA1. b-cat, b-catenin; BRL, BRMS1L. Bars correspond to mean±s.d. These data are representative of three independent experiments. Student’s t-test was used for the comparison of two independent groups in a,b,c,f,i.

Article Snippet: Protein extracts were resolved in 8–15% SDS–polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes and probed with antibodies against E-cadherin (1:1,000, 3195S, CST), vimentin (1:1,000, AF2105, R&D), BRMS1L (1:1,000, NBP2-14362, Novus), FZD10 (1:500, NBP100826, Novus), JNK (1:1,000, 9258, CST), p-JNK (1:1,000, Thr183/Tyr185, 4668S, CST), b-catenin (1:4,000, ab16051, Abcam) and b-actin (1:25,000, A3854, Sigma).

Techniques: Activity Assay, Luciferase, Transfection, Plasmid Preparation, Negative Control, Western Blot, Translocation Assay, Comparison

Figure 7 | BRMS1L inhibits liver metastasis of breast tumour xenografts without influencing orthotopic tumour incidence and growth rate. (a) The number of metastatic liver nodules in mice xenografted with breast cancer cells as indicated. The bars correspond to the mean±s.d. ***Po0.001 compared with GFP-shRNA. ###Po0.001 as compared with NC (n ¼ 8 per group). Student’s t-test was used for the comparison of two independent groups. (b) Expression of human HPRT mRNA relative to mouse 18S rRNA in the liver. Bars correspond to mean±s.d. Eight independent experiments were repeated (each mouse sample was considered as one independent experiment. Five technological replications were repeated in each sample.). Student’s t-test was used for the comparison of two independent groups. (c) Haematoxylin and eosin (H&E) staining for tumour xenografts and liver metastases of mice xenografted with breast cancer cells as indicated. Scale bars correspond to 50 mm. (d) Immunohistochemical staining for BRMS1L and FZD10 expression in tumour xenografts of mice xenografted with breast cancer cells as indicated. Scale bars correspond to 50 mm.BRL, BRMS1L.

Journal: Nature communications

Article Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.

doi: 10.1038/ncomms6406

Figure Lengend Snippet: Figure 7 | BRMS1L inhibits liver metastasis of breast tumour xenografts without influencing orthotopic tumour incidence and growth rate. (a) The number of metastatic liver nodules in mice xenografted with breast cancer cells as indicated. The bars correspond to the mean±s.d. ***Po0.001 compared with GFP-shRNA. ###Po0.001 as compared with NC (n ¼ 8 per group). Student’s t-test was used for the comparison of two independent groups. (b) Expression of human HPRT mRNA relative to mouse 18S rRNA in the liver. Bars correspond to mean±s.d. Eight independent experiments were repeated (each mouse sample was considered as one independent experiment. Five technological replications were repeated in each sample.). Student’s t-test was used for the comparison of two independent groups. (c) Haematoxylin and eosin (H&E) staining for tumour xenografts and liver metastases of mice xenografted with breast cancer cells as indicated. Scale bars correspond to 50 mm. (d) Immunohistochemical staining for BRMS1L and FZD10 expression in tumour xenografts of mice xenografted with breast cancer cells as indicated. Scale bars correspond to 50 mm.BRL, BRMS1L.

Article Snippet: Protein extracts were resolved in 8–15% SDS–polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes and probed with antibodies against E-cadherin (1:1,000, 3195S, CST), vimentin (1:1,000, AF2105, R&D), BRMS1L (1:1,000, NBP2-14362, Novus), FZD10 (1:500, NBP100826, Novus), JNK (1:1,000, 9258, CST), p-JNK (1:1,000, Thr183/Tyr185, 4668S, CST), b-catenin (1:4,000, ab16051, Abcam) and b-actin (1:25,000, A3854, Sigma).

Techniques: shRNA, Comparison, Expressing, Staining, Immunohistochemical staining

Figure 8 | Schematic summary of the miR106b-BRMS1L-FZD10 signalling pathway.

Journal: Nature communications

Article Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10.

doi: 10.1038/ncomms6406

Figure Lengend Snippet: Figure 8 | Schematic summary of the miR106b-BRMS1L-FZD10 signalling pathway.

Article Snippet: Protein extracts were resolved in 8–15% SDS–polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes and probed with antibodies against E-cadherin (1:1,000, 3195S, CST), vimentin (1:1,000, AF2105, R&D), BRMS1L (1:1,000, NBP2-14362, Novus), FZD10 (1:500, NBP100826, Novus), JNK (1:1,000, 9258, CST), p-JNK (1:1,000, Thr183/Tyr185, 4668S, CST), b-catenin (1:4,000, ab16051, Abcam) and b-actin (1:25,000, A3854, Sigma).

Techniques: